Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study

Shuhei Hara(Jikei University School of Medicine), Takahiro Kimura(Jikei University School of Medicine), Kagenori Ito(Jikei University School of Medicine), Masaki Hashimoto(Jikei University School of Medicine), Fumihiko Urabe(Jikei University School of Medicine), Kosuke Iwatani(Jikei University School of Medicine), Yushi Suhara(Jikei University School of Medicine), Naoya Tomomasa(Fuji Heavy Industries Health Insurance Society Ota Memorial Hospital), Wataru Fukuokaya(Jikei University School of Medicine), Shun Saito(Jikei University School of Medicine), Keiichiro Mori(Jikei University School of Medicine), Takafumi Yanagisawa(Jikei University School of Medicine), Yuji Yata(Jikei University School of Medicine), Eriko Nishi(Osaka Women's and Children's Hospital), Yusuke Takahashi(National Institute for Environmental Studies), Shunsuke Tsuzuki(Jikei University School of Medicine), Takahiro Oguchi(Tokyo Metropolitan Hiroo Hospital), Shiro Kurawaki(Jikei University School of Medicine), Jun Katami(Jikei University School of Medicine), Hirotaka Suzuki(Jikei University School of Medicine), Tatsuya Shimomura(Jikei University School of Medicine), S Takamizawa(Jikei University School of Medicine), Takayuki Sano, Soushi Kadena(Anjo Kosei Hospital), Keiichiro Miyajima(Jikei University School of Medicine)

International Journal of Clinical Oncology

May 20, 2024

Cited by 9

|American Journal of Physiology-Cell Physiology|2019|412

|British Journal of Cancer|2013|288

|Cancer Science|2018|282

|Clinical Cancer Research|2019|129

|Experimental & Molecular Medicine|2019|112

Related Papers